Description
The Domain Expert identified poor brain penetration as a major obstacle for galectin-3 targeting, but no existing compounds demonstrate adequate CNS exposure. This pharmacological gap limits therapeutic translation.
Source: Debate session sess_SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402 (Analysis: SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402)